Omenn Syndrome Medication

Updated: Mar 01, 2017
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Harumi Jyonouchi, MD  more...
  • Print

Medication SummaryReplacement therapy with IV immunoglobulin

Specific therapy for dermatitis and lymphadenitis involves immunosuppression with cyclosporine and the down-regulation of interleukin 4 (IL-4) [18] and interleukin 5 (IL-5) with interferon gamma. Broad-spectrum antibiotics are needed to treat invasive infections, especially those due to the common S aureus and gram-negative enteric bacteria. Prophylactic antibiotics and antifungal agents are often appropriate. Ancillary treatment with intravenous immunoglobulin (IVIG) replacement further decreases the risk of infection. Nutritional supplementation is mandatory to decrease the risk of infection and increase the likelihood of successful stem cell reconstitution.

Because Omenn syndrome tends to be fatal unless treated. Allogeneic hematopoietic stem cell transplantation (HSCT) represents a curative approach, but treatment-related complications and graft rejection must be overcome. One successful innovative effort used reduced-intensity conditioning allogeneic HSCT from a sibling donor, achieving full engraftment and successful immune reconstitution after allogeneic hematopoietic stem cell transplantation. [19] Although HSCT is the treatment of choice, allogeneic cord blood transplantation is another option recently used in one child. [20]

The overall consensus among clinical immunologists is that an intravenous immunoglobulin (IVIG) dose of 400-600 mg/kg/mo or a dose that maintains trough serum IgG levels greater than 500 mg/dL is desirable. [21] Patients with meningoencephalitis (X-linked agammaglobulinemia) require higher doses (1 g/kg) and, perhaps, intrathecal therapy. The measurement of preinfusion (ie, trough serum IgG levels every 3 mo until a steady state is achieved and then every 6 mo if the patient is stable) may be helpful in adjusting the dose of IVIG to achieve adequate serum levels. For persons in whom the catabolism of infused immunoglobulin G (IgG) is high, more frequent (eg, every 2-3 wk) infusions of smaller doses may maintain the serum level in the reference range. The rate of elimination of IgG may be higher during active infection; measuring serum IgG levels and adjusting to higher doses or shorter intervals may be required.

For replacement therapy for patients with primary immune deficiency, all brands of IVIG are probably equivalent, although differences in viral inactivation processes (eg, solvent detergent versus pasteurization and liquid versus lyophilized) are recognized. The choice of brands may depend on the hospital or home care formulary and on local availability and cost. The dose, manufacturer, and lot number should be recorded for each infusion to review for adverse events or other consequences. Recording of all adverse effects that occur during the infusion is crucial.

Periodic liver and renal function testing, approximately 3-4 times yearly, is also recommended. The US Food and Drug Administration (FDA) advises that, in patients at risk for renal failure, the recommended doses should not be exceeded and that infusion rates and concentrations should be the practical minimum levels. Examples of patients at risk for renal failure include those older than 65 years; those who use nephrotoxic drugs; and those with preexisting renal insufficiency, diabetes mellitus, volume depletion, sepsis, or paraproteinemia.

The initial treatment should be administered under the close supervision of experienced personnel. The risk of adverse reactions in the initial treatments is high, especially in patients with infections and in those in whom immune complexes form. In patients with active infection, infusion rates may need to be slower, and the dose halved (ie, 200-300 mg/kg). The remaining half should be given the next day to achieve a full dose. Treatment should not be discontinued. After normal serum IgG levels are achieved, adverse reactions are uncommon unless patients have active infections.

With the new generation of IVIG products, adverse effects are reduced. Adverse effects include tachycardia, chest tightness, back pain, arthralgia, myalgia, hypertension or hypotension, headache, pruritus, rash, and low-grade fever. More serious reactions are dyspnea, nausea, vomiting, circulatory collapse, and loss of consciousness. Patients with more profound immunodeficiency and patients with active infections have more severe reactions.

The anticomplementary activity of IgG aggregates in the IVIG and the formation of immune complexes are thought to be related to the adverse reactions. The formation of oligomeric or polymeric IgG complexes that interact with fragment crystallizable (Fc) receptors and that trigger the release of inflammatory mediators is another cause. Most adverse reactions are rate related. Slowing the infusion rate or discontinuing therapy until symptoms subside may diminish the reaction. Pretreatment with ibuprofen (5-10 mg/kg every 6-8 h), acetaminophen (15 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and/or hydrocortisone (6 mg/kg/dose; maximum, 100 mg) 1 hour before the infusion may prevent adverse reactions. In some patients with a history of severe adverse effects, therapy with analgesics and antihistamines may be repeated.

Acute renal failure is a rare but significant complication of IVIG treatment. Reports suggest that IVIG products with sucrose as a stabilizer may be associated with a greater risk for this renal complication. Acute tubular necrosis, vacuolar degeneration, and osmotic nephrosis are suggestive of osmotic injury to the proximal renal tubules. The infusion rate for sucrose-containing IVIG should not exceed 3 mg/kg/min based on the amount of sucrose. Risk factors for this adverse reaction include preexisting renal insufficiency, diabetes mellitus, dehydration, age older than 65 years, sepsis, paraproteinemia, and concomitant use of nephrotoxic agents. For patients at increased risk, monitoring the blood urea nitrogen and creatinine levels before starting the treatment and prior to each infusion is necessary. If the patient's renal function deteriorates, the treatment should be discontinued.

Immunoglobulin E (IgE) antibodies to immunoglobulin A (IgA) have been reported to cause severe transfusion reactions in patients with IgA deficiency. A few cases of true anaphylaxis have been reported in patients with selective IgA deficiency and common variable immunodeficiency who developed IgE antibodies to IgA after treatment with immunoglobulin. However, in actual experience this is rare. In addition, this is not a problem in patients with X-linked agammaglobulinemia (Bruton disease) or in those with severe combined immunodeficiency (SCID). Caution should be exercised in patients with IgA deficiency (< 7 mg/dL) who need IVIG because of IgG-subclass deficiencies. IVIG preparations with low concentrations of contaminating IgA are advised (see the Table below).

Table. Immune Globulin, Intravenous [22, 23, 21, 24] (Open Table in a new window)

Brand(Manufacturer) Manufacturing Process pH Additives (IVIG products containing sucrose are more often associated with renal dysfunction, acute renal failure, and osmotic nephrosis, particularly with preexisting risk factors [eg, history of renal insufficiency, diabetes mellitus, age >65 y, dehydration, sepsis, paraproteinemia, nephrotoxic drugs].) Parenteral Form and Final Concentrations IgA Content (mcg/mL)
Carimune NF

(CSL Behring)

Kistler-Nitschmann fractionation; pH 4 incubation, nanofiltration 6.4-6.8 6% solution: 10% sucrose, < 20 mg NaCl/g protein Lyophilized powder 3%, 6%, 9%, 12% Trace

(Grifols USA)

Cohn-Oncley fractionation, PEG precipitation, ion-exchange chromatography, pasteurization 5.1-6 Sucrose free, contains 5% D-sorbitol Liquid 5% < 50
Gammagard Liquid 10%

(Baxter Bioscience)

Cohn-Oncley cold ethanol fractionation, cation and anion exchange chromatography, solvent detergent treated, nanofiltration, low pH incubation 4.6-5.1 0.25M glycine Ready-for-use Liquid 10% 37

(Talecris Biotherapeutics)

Cohn-Oncley fractionation, caprylate-chromatography purification, cloth and depth filtration, low pH incubation 4-4.5 Contains no sugar, contains glycine Liquid 10% 46

(Bio Products)

Solvent/detergent treatment targeted to enveloped viruses; virus filtration using Pall Ultipor to remove small viruses including nonenveloped viruses; low pH incubation 4.8-5.1 Contains sorbitol (40 mg/mL); do not administer if fructose intolerant Ready-for-use solution 5% < 10
Iveegam EN

(Baxter Bioscience)

Cohn-Oncley fraction II/III; ultrafiltration; pasteurization 6.4-7.2 5% solution: 5% glucose, 0.3% NaCl Lyophilized powder 5% < 10
Polygam S/D

Gammagard S/D

(Baxter Bioscience for the American Red Cross)

Cohn-Oncley cold ethanol fractionation, followed by ultracentrafiltration and ion exchange chromatography; solvent detergent treated 6.4-7.2 5% solution: 0.3% albumin, 2.25% glycine, 2% glucose Lyophilized powder 5%, 10% < 1.6 (5% solution)

(Octapharma USA)

9/24/10: Withdrawn from market because of unexplained reports of thromboembolic events

Cohn-Oncley fraction II/III; ultrafiltration; low pH incubation; S/D treatment pasteurization 5.1-6 10% maltose Liquid 5% 200

(Swiss Red Cross for the American Red Cross)

Kistler-Nitschmann fractionation; pH 4, trace pepsin, nanofiltration 6.6 Per gram of IgG: 1.67 g sucrose, < 20 mg NaCl Lyophilized powder 3%, 6%, 9%, 12% 720
Privigen Liquid 10%

(CSL Behring)

Cold ethanol fractionation, octanoic acid fractionation, and anion exchange chromatography; pH 4 incubation and depth filtration 4.6-5 L-proline (approximately 250 mmol/L) as stabilizer; trace sodium; does not contain carbohydrate stabilizers (eg, sucrose, maltose) Ready-for use liquid 10% < 25

Immunosuppressive Agents

Class Summary

Specific therapy for dermatitis and lymphadenitis involves immunosuppression with cyclosporine and the down-regulation of IL-4 and IL-5 with INF-γ.

Cyclosporine (Sandimmune, Neoral)

Diarrhea and the youth of patients make high doses customary. Cyclic polypeptide that suppresses some humoral immunity and, to a greater extent, cell-mediated immune reactions such as delayed hypersensitivity, allograft rejection, experimental allergic encephalomyelitis, and GVHD in various organs. Dose based on patient's ideal body weight.



Class Summary

These agents are naturally occurring cytokines that possess various biologic functions, including immunosuppressive action. They are produced by cells in response to viruses, double-stranded RNA, antigens, or mitogens, and they are classified in relation to biochemical properties and the cell of origin. These agents are commercially produced by means of recombinant DNA technology. Interferon gamma has been administered subcutaneously on a daily basis to interrupt processes mediated by IL-4 and IL-5 and to enhance a functional inflammatory response to infection.

Interferon gamma-1b (Actimmune)

Recombinant-derived cytokine possessing antiviral, immunomodulatory, and antiproliferative activity. Differs from interferon alfa and interferon beta by possessing significant antiproliferative activity. The immunomodulatory effects also differ, unlike interferon alfa or interferon beta; interferon gamma has potent macrophage activating effects.